REPL
Same old tune, slightly different note
HC Wainwright tweaked its FY2026 EPS estimate for Replimune to $(3.35) from $(3.46), which is a tiny bit less gloomy — but not exactly a victory lap. The firm still kept its Sell rating, so the vibe here is more “we moved the decimal” than “pack your bags, bulls.”
Why investors should still care
This isn’t just random spreadsheet shuffling. Replimune is still dealing with the aftermath of the FDA’s CRL for lead candidate RP1, and that’s the real story hanging over the stock like a rain cloud at a beach day. When regulators slam the brakes, analysts don’t exactly start popping confetti.
The market’s weird little shrug
Shares popped about 14.7% to around $1.95 at one point, because biotech stocks can behave like caffeinated toddlers — dramatic, fast, and occasionally confusing. But the bigger picture is still ugly: the consensus stance sits at Reduce, with an average target of $4.75, and there are reports of planned workforce reductions too.
Big picture
A slightly smaller loss forecast is nice, sure. But until Replimune gets a cleaner regulatory path, the stock story is still mostly about damage control, not breakout growth.